November 2, 2021 at 10:00 AM ET (sign up here)
Please join us to review recent and upcoming clinical and regulatory developments in skin and auto-immune disease. Bloomberg Intelligence analyst Michael Shah, and Senior Principal of inThought Research Amanda Weyerbacher, PhD, will be joined by dermatologist Steven R. Feldman, MD, PhD and rheumatologist Christopher Ritchlin MD, MPH, for a discussion around prescribing trends, the competitive landscape and key mechanisms and drugs of interest, including the JAK class, Bimzelx, Dupixent and lebrikizumab.
- Michael Shah – European Biotech Analyst, Bloomberg Intelligence
- Amanda Weyerbacher, PhD – Senior Principal of inThought Research
- Christopher T. Ritchlin, MD, MPH – Chief – Department of Medicine , Allergy/Immunology and Rheumatology (SMD), University of Rochester Medical Center
- Steven R. Feldman, MD, PhD – Professor of Dermatology, Pathology and Public Health Sciences, Wake Forest University School of Medicine